View More Recent Stories
-
Ligand Pharma (LGND) PT Raised to $150 at Oppenheimer
-
Ligand Pharma (LGND) Introduces 2025 Guidance
-
Ligand Pharma (LGND) PT Raised to $141 at RBC Capital Ahead of Investor Day
-
Ligand Pharma (LGND) Tops Q3 EPS by 50c ; Offers Guidance
-
Ligand Pharma (LGND) PT Raised to $157 at H.C. Wainwright
-
RBC Capital Starts Ligand Pharma (LGND) at Outperform
-
Pieris Pharma (PIRS) and Palvella Therapeutics to Merge
-
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
-
Ligand Pharma (LGND) PT Raised to $140 at Craig-Hallum
-
Ligand Pharma (LGND) to Buy Apeiron Biologics for $100M Cash
-
H.C. Wainwright Reiterates Buy Rating on Ligand Pharma (LGND)
-
Ligand Pharma (LGND) Verona Pharma Announces FDA Approval of Ohtuvayre, First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

